Researchers have developed a novel biodegradable scaffold that locally delivers toll-like receptor 7/8 (TLR7/8) agonists, significantly improving immunotherapy efficacy against glioblastoma in preclinical models. This innovative approach harnesses immune activation within the brain tumor microenvironment, overcoming glioblastoma's notorious resistance to conventional therapies. The study provides promising preclinical evidence for a potential new treatment modality in one of the most aggressive and lethal brain cancers, offering hope for improved patient outcomes.